Available treatments psychiatrists have at present are limited in their effectiveness and

acceptability, with around 20 million people suffering from treatment-resistant depression (in the EU, the US and Japan).





This shows that current treatments are not working for a significant number of people suffering from depression. This is known as treatment-resistant depression.



Through the work of psychedelic pioneering groups and respected universities like John Hopkins and Imperial College London, new psychedelic therapies are being investigated and developed that can help treat patients where current treatment falls short. For example, psilocybin therapy involves a psychoactive substance found in so-called 'magic mushrooms' accompanied by supportive psychotherapy.



We are exploring attitudes amongst the general public towards different types of psychedelic therapies, compared to traditional interventions for patients suffering from treatment-resistant depression.





All responses are anonymous.

This survey will take approximately 5 minutes to complete.

OK